Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer

M. Agulnik*, E. N. Rhee, M. Yao, A. J. Mundt, L. E. Feldman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Many resected patients with locally advanced head and neck cancer are found on pathological assessment to have high-risk features for recurrence. We thus performed a feasibility trial of post-operative radiotherapy with paclitaxel and carboplatin in high-risk carcinoma of the head and neck. All patients were planned for 6 cycles of weekly paclitaxel (40 mg/m2) and carboplatin (AUC=1) and concomitant radiotherapy, 60 Gy in 6 weeks. The most common side effect was grade 3 and 4 mucositis in 5/6 patients and g-tube placement in 4/6 patients. Five out of 6 patients remain alive without evidence of disease at a mean time of 19 months since completion of therapy. Our pilot study treated 6 postoperative patients. Since 4 of 6 enrolled patients were unable to complete the treatment as prescribed, we conclude that this regimen is not feasible. With an 83% grade 3 or 4 mucositis rate and 67% of patients enrolled requiring feeding tube placement, this regimen is not tolerable.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalJournal of Chemotherapy
Volume17
Issue number2
DOIs
StatePublished - Apr 2005

Keywords

  • Chemotherapy
  • Head and neck cancer
  • Postoperative
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer'. Together they form a unique fingerprint.

Cite this